Scripps Research scientists train the immune system to make antibodies against numerous HIV strains Preclinical findings mark progress toward a long-sought vaccine capable of broad protection against HIV.
July 06, 2026
LA JOLLA, CA HIV is globally so diverse, consisting of hundreds of thousands of different strains, that antibodies capable of blocking one strain may not recognize another. This strain variability has been one of the greatest barriers to developing a vaccine that can provide broad protection against the virus. But rather than hoping the immune system stumbles onto the right antibodies, scientists at Scripps Research and collaborating institutions designed a series of immunizations to guide a subset of precursor B cells white blood cells that can mature into cells that release antibodies through a step-by-step training process termed germline-targeting sequential immunization. Each successive shot was engineered to activate the appropriate B cells and then nudge them closer to producing broadly neutralizing antibodies (bnAbs): rare antibodies that are able to recognize and block many different HIV strains.
For the first time, in a preclinical study of this vaccine strategy in non-human primates, the regimen generated functional bnAbs in serum, meaning the antibodies could neutralize many strains of HIV in laboratory tests. The findings, from scientists across Scripps Research, the La Jolla Institute for Immunology (LJI), Emory University, IAVI and other institutes, published in Nature on June 30, 2026, provide proof of principle for the germline-targeting strategy, showing that the immune system can be steered toward bnAbs that are expected to provide broad protection against HIV.
These antibodies were made to order in the sense that they recognized the exact site on HIV that the researchers set out to target and approached it at the intended angle. They also carried genetic features that the team had prespecified.
For years, a major question in HIV vaccine research has been whether we could guide the antibody-maturation process through multiple stages to a desired end result, says the study's co-senior author, Scripps Research professor William Schief, who's also the vice president of protein design in infectious disease research at Moderna, Inc. and the executive director of vaccine design at IAVI's Neutralizing Antibody Center. This work shows that the strategy can function as intended.
Earlier clinical trials led by Schief and his colleagues determined that germline targeting could consistently activate rare precursor B cells with the potential to become bnAb producers. A paper they published in 2025 then found that a follow-up booster immunization could move those cells further along the coveted path in clinical trials. However, those studies hadn't yet produced mature, functional bnAbs.
Such antibodies have long attracted interest because they can recognize parts of HIV that remain relatively similar across various strains. Some people naturally develop bnAbs after years of infection, but conventional HIV vaccination approaches haven't been able to reliably induce them.
Most former HIV vaccine candidates presented the immune system with versions of the virus's outer envelope protein (HIV Env) and relied on the right antibody response to emerge. That strategy faces an unusual obstacle: the rare precursor B cells generally don't recognize natural HIV Env well enough to be activated and eventually produce the right bnAbs.
Germline targeting takes a more directed approach. The first stage, called priming, uses an engineered vaccine component designed specifically to find and activate rare precursor B cells. Later boosters expose the cells to progressively more natural and diverse versions of HIV Env, encouraging them to accumulate the mutations needed to bind to the virus more tightly and recognize a wider range of strains. The regimen tested in this study focused on BG18, a particularly potent bnAb that targets a vulnerable region on HIV's surface.
The study also used saponin/MPLA nanoparticles (SMNP), an adjuvant developed by Howard Hughes Medical Institute Investigator Darrell Irvine, a professor and the Lita Annenberg Hazen Chair at Scripps Research. Adjuvants are typically added to protein-based vaccines to strengthen the immune response, and SMNP was likely critical to the study's success.
Activating rare precursor B cells was the starting point, notes co-first author Jon Steichen, an institute investigator at Scripps Research. Each new immunization had to keep the BG18-class cells engaged while asking them to recognize a more difficult and realistic version of HIV Env.
The project began by testing three candidates for the first booster. When all three successfully reactivated the targeted cells, the team extended the study to see how far it could take the response. The researchers tracked immune responses for over two years as they tested a priming phase followed by seven boosters, with comprehensive B cell analyses led by co-first author Patrick Madden, an instructor in the laboratory of co-corresponding author Shane Crotty, a professor and the chief scientific officer at LJI. Throughout that period, the targeted classes of B cells continued to survive and accumulate mutations that improved their ability to recognize diverse HIV variants.
After the fifth booster, 78% of primates receiving the sequential regimen still had detectable BG18-class responses. High-resolution structural imaging by the laboratory of Scripps Research professor Andrew Ward confirmed that the antibodies were binding to HIV Env as intended, rather than reaching the same target through an unplanned route.
More than half of the group receiving the full regimen developed bnAb lineages capable of blocking multiple HIV strains. One of th
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
06/09/2026
June 9 2026, 23:00 (PDT) Dolby and MagentaTV Bring Fans Closer to the FIFA Worl...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
07/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/07/2026
New appointments to Screen Australia board 7 July 2026
The Albanese Labor Government has made new appointments to the Screen Australia board.
Dr Tania Chamber...
07/07/2026
The right team. The right time.' How The Killings at Parrish Station stuck t...
07/07/2026
Berklee College of Music Alum and Faculty Perform at Boston Public Library's...
07/07/2026
Scripps Research scientists train the immune system to make antibodies against numerous HIV strains Preclinical findings mark progress toward a long-sought vacc...
06/07/2026
Long-developed relationships and informal access, three production models, and c...
06/07/2026
The deal follows Lumine's recent acquisition of Synamedia's video-networ...
06/07/2026
This former SportsCenter producer is shaping local-team studio coverage to surro...
06/07/2026
IMS Productions and FOX Sports deployed more than 100 cameras, 32 onboard feeds,...
06/07/2026
Lumine Group Inc. has announced the completion of its acquisition of the Video Network Business from Synamedia. The business will operate as a standalone compan...
06/07/2026
NASCAR has announced a content and commercial partnership with Motorsport Network, a motorsports and automotive media platform, to distribute NASCAR original co...
06/07/2026
Versant Media Group has announced a definitive agreement to acquire Full Swing, a sports technology company, from Bruin Capital and a group of minority investor...
06/07/2026
DAZN has announced global broadcast rights to 3ICE, a professional hockey format featuring three skaters and a goalkeeper per side, with no power plays or offsi...
06/07/2026
Bundle gains 100 new synths & more
Synth Anthology 5 the largest and most feature-packed edition of UVI's hardware synth emulation bundle, bringing toge...
06/07/2026
Available now via free firmware update
MOTU have just announced that three of their popular audio interfaces now boast official Milan Certification. The 16A...
06/07/2026
Rohde & Schwarz completes Hunter Preliminary Design Review for the Integrated Co...
06/07/2026
The R&S IMAGER from Rohde & Schwarz uses millimeter wave imaging to inspect the ...
06/07/2026
The National Film and Video Foundation (NFVF), an agency of the Department of Sp...
06/07/2026
Digital Domain Appoints Industry Veteran Patrick Davenport as Executive Vice Pre...
06/07/2026
Gravity Media USA appoints Brittney Boston as Head of Business Development
Brie Clayton July 6, 2026
0 Comments
The strategic new appointment supports...
06/07/2026
Remote Editing Without Cloud Storage in Resolve
Michael Cioni July 6, 2026
0 Comments
This is a step-by-step guide that demonstrates how to setup your...
06/07/2026
Automatic Caption Translation in Adobe Premiere Pro
Colin Smith July 6, 2026
0 Comments
Here I showcase the innovative automatic caption translation f...
06/07/2026
Flavor's First Ever Managing Director Neal Cohen Retires; Longstanding Execu...
06/07/2026
How Adam Rosenwach Pivoted from Music to Medtech Without Missing a Beat What do the rehearsal room and the boardroom have in common? More than you might think...
06/07/2026
Zhongyi Optics unveils the Dreamy Zone T1 FF Cine Lens Series on Indiegogo with ...
06/07/2026
Open source AI has shown how quickly developers can innovate when models, data a...
06/07/2026
Techtel debuts insyght: making ST 2110 media discovery easy
intellisphereinsyght2026
6 July Written By Suzanne Costello
Sydney, Australia - 06 July 2026 T...
06/07/2026
Monday 6 July 2026
Sky agrees to acquire ITV Media & Entertainment, creating a ...
06/07/2026
Fresh from his World Cup heroics with Cabo Verde, Roberto Pico' Lopes will join the RT panel for Argentina v Egypt tomorrow and for the England v Norway q...
06/07/2026
Nations have long invested in domestic infrastructure to advance their economies, protect and use their data, and take advantage of technology opportunities in ...
06/07/2026
Every year, the International Conference on Machine Learning (ICML) reveals where thousands of AI researchers have decided to put their work.
This year's ...
06/07/2026
A death can be unsuspicious, but it has to be explained
What happened to Ke...
05/07/2026
We've gone to another level of integrating the graphics into the set architecture' - Zac Fields, SVP, Graphic Technology and Integration, FOX Sports...
05/07/2026
Browser-based and desktop apps available
Digital Sunset Studios have been busy working on an interesting project: a free software tool that provides compute...
04/07/2026
When Canada qualified for the FIFA World Cup 2026, OneSoccer knew this wasn'...
04/07/2026
Celebrates company's 80th anniversary
Rhodes have recently revealed that they will be producing a limited run of electric pianos in celebration of their...
04/07/2026
Blackmagic Design Cameras Empower Youth Broadcasting Program
Brie Clayton July 3, 2026
0 Comments
Blackmagic Pocket Cinema Camera 6K Pro and Blackmagi...
04/07/2026
iZotope Joins Boris FX
Boris Yamnitsky July 3, 2026
0 Comments
iZotope, the team behind RX and Ozone, is joining Boris FX. A letter from founder Boris...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
03/07/2026
New bundle & three Single Packs
Continuing to expand their already sizeable orchestral collection, VSL's latest release introduces three new Single Pack...
03/07/2026
Venue installs new ATC-equipped control room
LSO St Luke's, a unique music venue that also serves as the home of the London Symphony Orchestra, have rec...
03/07/2026
Caden Pearson appointed new Commissioning Editor for NITV
3 July, 2026
Media releases
National Indigenous Television (NITV) has strengthened its commitment...
03/07/2026
1 February 2023
SHARE Facebook Twitter Linkedin Email
Munich, Germany, 1st February 2023: Cinegy GmbH, the premier provider of software technology for digit...
03/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
03/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
Scripps Research scientists train the immune system to make antibodies against numerous HIV strains Preclinical findings mark progress toward a long-sought vaccine capable of broad protection against HIV.
